Evidence map›Paper›PMID 32181531›Full record

ArticleThe oncologist2020

Comprehensive Evaluation of Relapse Risk (CERR) Score for Colorectal Liver Metastases: Development and Validation.

Yijiao Chen, Wenju Chang, Li Ren, Jingwen Chen, Wentao Tang, Tianyu Liu, Mi Jian, Yu Liu, Ye Wei, Jianmin Xu

Abstract read
In one paragraph

Article in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Resection of Colorectal Liver Metastases: Prognostic Impact of Tumor Burden Score Varies with Unilateral Versus Bilateral Metastatic Spread.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yijiao Chen *Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Wenju Chang *Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Li Ren *Colorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Jingwen ChenColorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Wentao TangColorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Tianyu LiuColorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Mi JianColorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Yu LiuColorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
Ye WeiColorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.ORCID 0000-0003-1994-5664
Jianmin XuColorectal Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe calculation of the tumor burden score (TBS) is not perfect because the bilobar spread of colorectal liver metastasis (CRLM) is neglected. The identification of an ideal prognostic scoring system for CRLM remains controversial. MATERIALS AND

methodsPatients who underwent curative intent liver resection for CRLM from one medical center were enrolled in cohort 1 (787 patients) and cohort 2 (162 patients). Tumor relapse-free survival (RFS) was the main outcome. A Cox regression model was used to identify independent predictors of prognosis. The time-dependent area under the curve, calibration curve, and C-index were employed to validate the predictive ability of the survival model.

resultsModified TBS (mTBS) was established by a mathematical equation with parameters including CRLM size, CRLM number, and unilobar or bilobar metastasis. Five preoperative predictors of worse RFS were identified in cohort 1 and incorporated into the Comprehensive Evaluation of Relapse Risk (CERR) score: KRAS/NRAS/BRAF-mutated tumor (1 point); node-positive primary (1 point); extrahepatic disease (1 point); carcinoembryonic antigen level > 200 ng/mL or carbohydrate antigen 19-9 (CA19-9) >200 U/mL (1 point); and mTBS between 5 and 11 (1 point) or 12 and over (2 points). Patients in cohort 1 were stratified by their CERR score into risk groups: the high-risk group (CERR score 4 or more), the medium-risk group (CERR score 2-3), and the low-risk group (CERR score 0-1). Importantly, internal validation in cohort 1 and further validation in cohort 2 both showed the superior discriminatory capacity of the CERR score.

conclusionmTBS should be promoted. The CERR score is a powerful prognostic tool that can help determine optimal clinical management strategies. IMPLICATIONS FOR PRACTICE: This work resulted in the successful modification of the tumor burden score and development of a comprehensive and practical prognostic scoring system-the Comprehensive Evaluation of Relapse Risk (CERR) score. The CERR score, with a better prognostic discriminatory ability, outperformed the Fong score. Perhaps more importantly, the CERR score is a powerful prognostic tool because it unified the most consistently reported prognostic factors. Therefore, the CERR score can assist doctors in determining optimal clinical management strategies.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsHepatectomyHumansNeoplasm Recurrence, LocalPrognosisRetrospective StudiesColorectal cancerHepatectomyMetastasisPrognosisRelapse

Identifiers

PMID32181531
PMCPMC7356794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.